Rubiscolin-6 activates opioid receptors to enhance glucose uptake in skeletal muscle.
AMP-Activated Protein Kinases
/ genetics
Animals
Biological Transport
Diabetes Mellitus, Experimental
/ drug therapy
Glucose
/ metabolism
Glucose Transporter Type 4
/ genetics
Humans
Male
Muscle, Skeletal
/ drug effects
Peptide Fragments
/ administration & dosage
Rats
Rats, Wistar
Receptors, Opioid
/ genetics
Ribulose-Bisphosphate Carboxylase
/ administration & dosage
AMPK
GLUT4
Glucose uptake
Opioid receptor
Rubiscolin-6
Journal
Journal of food and drug analysis
ISSN: 2224-6614
Titre abrégé: J Food Drug Anal
Pays: China (Republic : 1949- )
ID NLM: 101630927
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
21
06
2018
accepted:
25
06
2018
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
24
3
2020
Statut:
ppublish
Résumé
Rubiscolin-6 is an opioid peptide derived from plant ribulose bisphosphate carboxylase/oxygenase (Rubisco). It has been demonstrated that opioid receptors could control glucose homeostasis in skeletal muscle independent of insulin action. Therefore, Rubiscolin-6 may be involved in the control of glucose metabolism. In the present study, we investigated the effect of rubiscolin-6 on glucose uptake in skeletal muscle. Rubiscolin-6-induced glucose uptake was measured using the fluorescent indicator 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglucose (2-NBDG) in L6 and C2C12 cell lines. The protein expressions of glucose transporter 4 (GLUT4) and AMP-activated protein kinase (AMPK) in L6 cells were observed by Western blotting. The in vivo effects of rubiscolin-6 were characterized in streptozotocin (STZ)-induced diabetic rats. Rubiscolin-6 induced a concentration-dependent increase in glucose uptake levels. The increase of phospho-AMPK (pAMPK) and GLUT4 expressions were also observed in L6 and C2C12 cells. Effects of rubiscolin-6 were blocked by opioid receptor antagonists and/or associated signals inhibitors. Moreover, Rubiscolin-6 produced a dose-dependent reduction of blood glucose and increased GLUT4 expression in STZ-induced diabetic rats. In conclusion, rubiscolin-6 increases glucose uptake, potentially via an activation of AMPK to enhance GLUT4 translocation after binding to opioid receptors in skeletal muscle.
Identifiants
pubmed: 30648580
pii: j.jfda.2018.06.012
doi: 10.1016/j.jfda.2018.06.012
pmc: PMC9298623
doi:
Substances chimiques
Glucose Transporter Type 4
0
Peptide Fragments
0
Receptors, Opioid
0
rubiscolin 6
0
AMP-Activated Protein Kinases
EC 2.7.11.31
Ribulose-Bisphosphate Carboxylase
EC 4.1.1.39
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-274Informations de copyright
Copyright © 2018. Published by Elsevier Taiwan LLC.
Références
Curr Protoc Pharmacol. 2015 Sep 01;70:5.47.1-5.47.20
pubmed: 26331889
Br J Pharmacol. 2018 Jul;175(14):2737-2749
pubmed: 28394427
Mol Nutr Food Res. 2012 Aug;56(8):1315-23
pubmed: 22715053
Cell Metab. 2018 Feb 6;27(2):299-313
pubmed: 29153408
Metabolism. 2001 Dec;50(12):1402-8
pubmed: 11735084
Nature. 1999 Jun 17;399(6737):697-700
pubmed: 10385123
Diabetes. 2001 Dec;50(12):2815-21
pubmed: 11723065
Mol Pharmacol. 2003 Jan;63(1):89-95
pubmed: 12488540
J Appl Physiol (1985). 2005 Dec;99(6):2181-8
pubmed: 16099889
Neurosci Lett. 2009 Nov 13;465(2):177-80
pubmed: 19682542
Cells. 2014 Mar 05;3(1):152-79
pubmed: 24709907
Biophys Rev. 2016 Mar;8(1):5-9
pubmed: 28510148
Drug Des Devel Ther. 2016 Jul 07;10:2193-202
pubmed: 27462144
J Agric Food Chem. 2007 Oct 3;55(20):8101-4
pubmed: 17803260
J Neurochem. 1994 Mar;62(3):1009-14
pubmed: 8113787
Peptides. 2003 Feb;24(2):325-8
pubmed: 12668220
Circ Res. 2007 Feb 16;100(3):328-41
pubmed: 17307971
Nutr Metab (Lond). 2012 Nov 27;9(1):106
pubmed: 23186010
J Neurosci. 2000 Nov 15;20(22):RC110
pubmed: 11069979
J Clin Invest. 1984 Oct;74(4):1473-80
pubmed: 6148357
Anesthesiology. 2011 Dec;115(6):1363-81
pubmed: 22020140
FEBS Lett. 2001 Dec 7;509(2):213-7
pubmed: 11741591
ACS Chem Neurosci. 2012 Sep 19;3(9):720-7
pubmed: 23019498
Curr Pharm Des. 2003;9(16):1325-30
pubmed: 12769740
Diabetes. 2005 May;54(5):1573-80
pubmed: 15855348
Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):101-106
pubmed: 29050941
Peptides. 2003 Apr;24(4):503-8
pubmed: 12860192
Annu Rev Med. 2016;67:433-51
pubmed: 26332001
Mini Rev Med Chem. 2018;18(2):104-112
pubmed: 28462718
J Biochem Biophys Methods. 2005 Sep 30;64(3):207-15
pubmed: 16182371
Endocrinology. 2003 May;144(5):1753-60
pubmed: 12697680
Psychopharmacology (Berl). 2007 Apr;191(3):497-506
pubmed: 17031710
Nat Cell Biol. 2011 Sep 02;13(9):1016-23
pubmed: 21892142
Curr Top Med Chem. 2004;4(1):1-17
pubmed: 14754373
Cell Metab. 2007 Apr;5(4):237-52
pubmed: 17403369
Peptides. 2007 Oct;28(10):1998-2003
pubmed: 17766012
Br J Pharmacol. 2011 Jun;163(3):624-37
pubmed: 21250979
Mol Pharmacol. 2012 Feb;81(2):154-65
pubmed: 22031472
Pharmacotherapy. 2017 Sep;37(9):1105-1121
pubmed: 28699646
Acta Physiol Scand. 2003 Aug;178(4):337-45
pubmed: 12864738